Catalyst Edge · Scanner · Tickers · EXOZ
CATALYST DOSSIER · UPDATED 2026-10-20

$EXOZ

Unclassified · convergence — · conviction —
Convergence Score
—
Conviction
—
Signals Firing
0
Track Record
2/8
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $EXOZ?

EXOZ -19 AVOID biotech

Quantitative

  • Net Income (CY2026Q2): $-2.9M (-22.0% YoY)

Catalysts

  • Multi-spoke convergence: 2 convergent signals fired: halt, auto_macro_options_gex

Risks

  • Position-sizing discipline: Conviction AVOID (-19 score) — size accordingly; no specific catalyst-fade risk flagged

Bear case

  • Multiple compression: If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis

Sympathy basket (cerebro)

  • DK via energy r=-0.97 divergent (score 22)
  • GEVO via energy r=-0.97 divergent (score -10)
  • NFE via utilities r=-0.87 divergent (score 16)
  • EVRG via utilities r=-0.87 divergent (score 9)
  • MOD via consumer r=+0.68 sympathetic (score 18)
  • SYY via consumer r=+0.68 sympathetic (score 8)

Signals Firing

No active signals this cycle.
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Pick Track Record

DateListNext-day max runNext-day closeHit +2%?
2026-10-09sec_top_gappers+1.0%-3.8%—
2026-10-09sec_top_moat_emerging+1.0%-3.8%—
2026-09-30sec_top_gappers-1.2%-1.2%—
2026-09-30sec_top_moat_emerging-1.2%-1.2%—
2026-09-29sec_top_gappers+1.6%-4.4%—
2026-09-29sec_top_moat_emerging+1.6%-4.4%—
2026-09-18sec_top_gappers+8.5%-4.6%✓ hit
2026-09-18sec_top_moat_emerging+8.5%-4.6%✓ hit
Lifetime: 2/8 wins · hit-rate 25.0% on +2% intraday

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.